IntroductionAccording to our national data based on PREDATORR study, the point prevalence of diabetes mellitus in Romania was 11.6 % in adults between 20 and 79 years old. Unequivocally, type 2 diabetes mellitus is highly correlated with psychological and personality factors.ObjectivesThe objective of our research was to evaluate the frequency of type D personality in patients suffering from type 2 diabetes and its influence on angiopathic complications.MethodsA cross-sectional study was conducted in 173 patients with type 2 diabetes who were self-assessed by using Beck Depression Inventory I, STAI-Y scale and DS 14 scale for detection of type D personality.ResultsBoth depression (p = 0.012) and state and trait anxiety (p = 0.019 and 0.023 respectively) scores were significantly higher in diabetic patients with type D personality compared with non-type D diabetic patients. Lower limb complications were more frequent in non-type D personality diabetics (p = 0.018) while diabetic retinopathy and diabetic polyneuropathy (p = 0.004 and p = 0.010 respectively).ConclusionsThe presence of type D personality has a supplementary negative impact on type 2 diabetic patients’ affectivity and emotions. On the one hand, the more frequent microangiopathic complications in type D personality diabetic patients confirm that diabetes, at least in part, is an endovascular disease. On the other hand, some factors such as pro-inflammatory biomarkers may be more expressed in type 2 diabetic patients with concomitantly type D personality than those without this type of personality, leading to premature microangiopathic complications.
IntroductionMajor depressive disorder (MDD)is one of the most common psychiatric disorders and a large number of patients present a poor response to treatment. Shortening of telomeres physiologically occurs after each cell division and their shortening is also associated with cell ageing. Studies are affirming that patients who suffer from mental illnesses have shorter telomeres in comparison with patients without such affections. 4 The effect of antidepressant medication on the biology of the telomeres was studied very little in humans and the current data suggest that the length of telomeres is a promising target regarding the prognosis and the response to psychotropic treatment.ObjectivesTo analyze the telomere length (TL) from peripheral blood DNA of patients with major depressive disorder (MDD) compared to healthy controls. A second objective was to compare the TL of patients in relation to antidepressant treatment.MethodsWe analysed the clinical data from 16 patients admitted to the Psychiatry Clinic of Timisoara with the diagnosis of MDD and 10 healthy controls. The collection of clinical data was carried out in a structured and standardized manner both on paper and electronically, and the Hamilton Depression Rating Scale (HDRS) was applied to assess the severity of depression. Also, blood samples were collected, and plasma and white blood cells (WBC) were separated by centrifugation. Patients’ samples were collected before and after 12 weeks of escitalopram antidepressant treatment, and a structured diagnostic interview and a standardized depression rating scale were done. DNA was extracted from WBC using the QIAamp DNA Mini Kit (Qiagen), and TL was determined by real time PCR using the Absolute Human Telomere Length Quantification qPCR Assay Kit (Sciencell Research Laboratories) according to the manufacturers’ specifications. The TL expressed as megabases/diploid cell (Mb/DC) were compared between cases and controls using a Mann-Whitney test, and between patients before and after treatment using a Wilcoxon matched-pairs signed rank statistical test.ResultsThe mean±SD telomere length for healthy controls was 0.3614±0.082Mb/DC, for treatment naïve patients was 0.4513±0.199Mb/DC, and for patients after treatment was 0.3476±0.070Mb/DC. There was no statistical significant difference in TL between patients and controls (p=0.266), nor between patients before and after treatment (p=0.055).ConclusionsIn this pilot project of limited sample size there was no difference in TL between MDD patients and healthy controls. Moreover, the TL of patients did not significantly change after 12 weeks of escitalopram antidepressant treatment.Disclosure of InterestNone Declared
Introduction Suicide is one of the most frequent causes of death in schizophrenia patients, but the low insight in this pathology makes it difficult to identify persons at risk. The clinical picture of schizophrenia includes a wide variety of signs and symptoms, which make it hard to properly assess suicidal ideation. Objectives Our study was aimed at comparing tendencies among the clinical presentation and sociodemographic factors of schizophrenic patients with and without suicide attempts in their medical history. Methods We analysed the clinical data of 60 patients admitted to the Psychiatry Clinic of Timisoara with the diagnosis of Schizophrenia during 2020-2021. The PANNS-R scale was used for every patient, and each item was compared to the clinical data gathered. Results A positive history of suicide attempts was corelated to blunted affect, stereotyped thinking, lack of spontanety and flow of conversation, somatic concern, tension, unsual tought content, lack of judgment and insight. Total negative symptoms were correlated with psychiatric family history. Conclusions Considering a history of suicide attempts is a risk factor for suicide, more studies are needed to evaluate patients with such a history in order to identify the constelation of risk factors with a high predictibility value for suicide. This could help implement prophylactic measures in clinical practice that would decrease suicidal behaviour in schizophrenia. Disclosure No significant relationships.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.